Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SLAM DRILLS MORE COPPER MINERALIZATION AT GOODWIN (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News bluebird bio Inc BLUE

Healthcare Biotechnology
bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. Its lead gene therapy programs for sickle cell disease, B-thalassemia, and cerebral adrenoleukodystrophy and is advancing research to apply new... see more

Recent & Breaking News (NDAQ:BLUE)

bluebird bio to Present at Two Investor Conferences in November

Business Wire November 1, 2016

Tailwinds Continue To Hold The Street's Gaze Toward Bluebird Bio Aloft

Benzinga.com  October 14, 2016

18 Stocks Moving In Friday's Pre-Market Session

Benzinga.com  October 14, 2016

Exclusive: SunTrust Managing Director Discusses Bluebird Bio, A Leader In Gene Therapy

Benzinga.com  October 13, 2016

bluebird bio Provides Update on LentiGlobin™ Programs and Research and Development Strategy at Gene Therapy Day

Business Wire October 13, 2016

bluebird bio Announces Topics for Gene Therapy Day, October Investor Presentation

Business Wire October 6, 2016

bluebird bio and Medigene Establish Strategic T Cell Receptor (TCR) Alliance in Cancer Immunotherapy

Business Wire September 29, 2016

Biotech Stocks on Investors' Radar -- Portola Pharma, bluebird bio, Auris Medical, and Cerulean Pharma

PR Newswire September 22, 2016

LentiGlobin™ Investigational Gene Therapy for Transfusion-Dependent Beta-Thalassemia Accepted into European Medicines Agency’s PRIME Program

Business Wire September 21, 2016

Benzinga's Volume Movers

Benzinga.com  September 15, 2016

bluebird bio Announces Webcast of Gene Therapy Day

Business Wire September 9, 2016

bluebird bio Opens Phase 3 Study of LentiGlobin™ Drug Product in Patients with Transfusion-Dependent Beta-Thalassemia

Business Wire September 8, 2016

bluebird bio to Present at Four Upcoming Conferences

Business Wire August 30, 2016

bluebird bio to Present at Wedbush PacGrow Healthcare Conference

Business Wire August 4, 2016

bluebird bio Reports Second Quarter 2016 Financial Results and Recent Operational Progress

Business Wire August 3, 2016

bluebird bio Presents megaTAL Genome Editing Data at American Society of Hematology (ASH) Workshop on Genome Editing

Business Wire July 18, 2016

Biotechnology Equities at a Glance -- MannKind, bluebird bio, OncoGenex Pharma, and Hevat Biologics

PR Newswire June 27, 2016

bluebird bio to Present at Goldman Sachs 37th Annual Healthcare Conference

Business Wire May 23, 2016

bluebird bio Presents Oncology and Gene Therapy Data at the ASGCT 19th Annual Meeting

Business Wire May 9, 2016

bluebird bio Reports First Quarter 2016 Financial Results and Recent Operational Progress

Business Wire May 4, 2016